Is Ketamine Right for You?

A page with this title is usually designed to reach one conclusion. This one is not. There are presentations where ketamine is a strong option, presentations where something cheaper and better-evidenced should come first, and presentations where we will decline.

Two trials
Adequate Antidepressant Attempts Before This Is the Right Question
6-8 wks
What Counts as an Adequate Trial at a Therapeutic Dose
Screened
Bipolarity and Suicide Risk, Before Any Prescribing
Declined
A Real Outcome, Assessed Before You Pay

What Should Usually Come First

Ketamine is a reasonable option for treatment-resistant presentations, and treatment-resistant means something specific: adequate trials that failed, not brief trials abandoned early. A large share of people who describe themselves as treatment-resistant have had subtherapeutic doses, courses stopped at three weeks because nothing had happened yet, or therapy that was supportive rather than protocol-driven. Sorting that out is worth more than any medication decision.

  • An adequate antidepressant trial is a therapeutic dose for six to eight weeks
  • Stopping at two or three weeks is common and is not a failed trial
  • Evidence-based therapy means CBT, EMDR or ERP, not general talk therapy
  • Sleep disorders, thyroid disease and anemia mimic depression and are checkable
  • Alcohol used nightly will keep depression in place regardless of treatment

Where the Case Is Strongest

The evidence is best for treatment-resistant depression, where the trial literature is largest and most replicated. PTSD is next, with randomized trials run in PTSD populations. Bipolar depression has add-on evidence and requires a mood stabilizer. Beyond that the support thins quickly, and we would rather point that out than let a page imply uniform strength across every indication.

  • Treatment-resistant depression: the largest and most replicated evidence base
  • PTSD: randomized trials conducted in PTSD patients specifically
  • Bipolar depression: add-on evidence, mood stabilizer required
  • Anxiety, OCD and chronic pain: real but thinner, each with caveats
  • Burnout without depression: no evidence, and not something we treat

When Ketamine Is the Wrong Answer

Some situations call for a different intervention and saying so is more useful than a broad invitation. If you are in crisis, telehealth is not the right level of care. If your pain is the primary complaint, an infusion clinic usually fits better. If you have never had ERP and you have OCD, that is the higher-value step by a wide margin.

  • Active suicidal planning needs emergency or inpatient care, not telehealth
  • Primary chronic pain is usually better served by an infusion clinic
  • OCD without a genuine ERP course should start there instead
  • Untreated substance use disorder needs addressing first
  • A first depressive episode with no medication trial should start with one

Absolute Exclusions

These are assessed before any payment and are not negotiable. Listing them here rather than in the small print is deliberate.

  • Uncontrolled hypertension or significant cardiovascular disease
  • Active psychosis, schizophrenia, or untreated bipolar mania
  • Active substance use disorder, including alcohol use disorder
  • Pregnancy or breastfeeding
  • Under 18
  • No sober support person available for sessions

How to Answer the Question With Data

Rather than deciding from a marketing page, use the instruments. Screening is scored in your browser, nothing is saved unless you choose to save it, and no payment is required to find out where you stand. If the numbers say something other than what you expected, that is the page doing its job.

  • PHQ-9 for depression severity and a baseline to measure against
  • GAD-7 where anxiety is the more prominent complaint
  • MDQ for bipolarity, which changes the plan substantially if positive
  • C-SSRS where suicidal thoughts are present, to determine the right level of care
  • All scored in your browser, before any consultation or payment

The Evidence Behind the Recommendation Hierarchy

A 64% response rate against 28% for the active control at 24 hours in treatment-resistant depression. The strongest indication, and the reason treatment-resistant depression sits at the top of the hierarchy on this page. (Murrough et al., 2013 (American Journal of Psychiatry))

A randomized controlled trial of repeated ketamine dosing in chronic PTSD against midazolam, supporting PTSD as the second strongest indication because the evidence was generated in PTSD patients rather than extrapolated. (Feder et al., 2021 (American Journal of Psychiatry))

The American Psychiatric Association consensus statement on ketamine in mood disorders, which is the source of the patient selection and exclusion criteria applied here. (Sanacora et al., 2017 (JAMA Psychiatry))

Frequently Asked Questions

How do I know if I am actually treatment-resistant?

Two adequate antidepressant trials that failed, where adequate means a therapeutic dose sustained for six to eight weeks. Many people who believe they are treatment-resistant have not had that: doses stayed low, or a trial was stopped at three weeks before it could work. It is worth reviewing your actual history with a clinician before concluding medication does not work for you, because the cheaper answer is often still available.

Do I need a formal diagnosis first?

You need a diagnosis, though not necessarily one made before you contact us. The consultation is a diagnostic evaluation. What you cannot do is self-diagnose your way to a prescription; if screening and evaluation point somewhere other than where you expected, that changes what is appropriate.

What if I am declined?

It happens, and it happens before you pay for a course rather than after. Usual reasons are uncontrolled blood pressure, a positive bipolar screen without psychiatric care in place, active substance use, or a suicide risk level that needs more than telehealth. In each case there is a next step, and we will tell you what it is rather than leaving you with a refusal.

Is it worth trying if nothing else has worked?

Often yes, and that is close to the population the trials were run in. Two caveats worth holding: roughly a third of patients in those trials did not respond, and durability varies, so most people need a course rather than a single dose and some need maintenance. Going in expecting a cure sets up a disappointment the treatment does not deserve.

Dr. Ben Soffer, D.O., Medical Director, Tovani Health
Medically reviewed

Dr. Ben Soffer, D.O.

Medical Director, Tovani Health

Board-certified in Internal Medicine (ABIM) · Licensed in Florida, New Jersey & California

Dr. Soffer is a board-certified physician and the founder and sole prescribing clinician at Tovani Health. He personally reviews every patient’s eligibility and oversees at-home ketamine treatment for depression, anxiety, PTSD, and chronic pain.

Last reviewed August 2026 · About the physician

Go deeper: clinical guides

Plain-English, evidence-based guides: what the condition is, what helps, and where ketamine fits. Educational, not a diagnosis.

Ready to Start Healing?

Check your eligibility in under 5 minutes. Free, no obligation.